““This year [a different vaccine] Completely unnecessary. But in the middle of next year it could be a different situation.”
Ugur Sahin, CEO of Biotech, told the Financial Times in an interview that the Covid-1 possibility could probably change in a way that it could escape the vaccine and the immune system.
A COVID vaccine, developed by Biotech BNTX
And Pfizer PFE,
Using mRNA technology to help fight global epidemics, 1.5 billion doses were sent to more than 1 billion countries by the end of September, according to a company presentation. The vaccines and booster shots currently available are strong enough for current strains, including highly contagious deltas, but the virus has just begun the process of evolving, Sahin said in an interview published Sunday.
We have no reason to assume that the next generation of viruses will be easier for the immune system to handle than the current generation, ”said Sahin, who is focusing on booster shots for vaccination next year and those who have not seen continued vaccination efforts.
Last week, the financial markets were happy with the news of Mark MRK,
And experimental oral antiviral therapy for Covid-1 for Rizback Therapeutics. The third-stage test, Sadh, Molnupirvir, reduced the risk of hospitalization or death by 50% and was found to work against gamma, delta and mu variants among about 40% of participants for whom sequencing was available.
Read: Why you can change the direction of a pill epidemic at home
Medical experts warn that although Mark’s potential groundbreaking new treatment may be used by some as an excuse not to be vaccinated. “It’s not a magic pill,” said Dr. William Schaffner, a professor in the Department of Infectious Diseases at Vanderbilt University Medical Center.
Read: Fawcett said legitimate claims of religious exemption from the vaccine mandate were rare